Regarding the safety outcomes, using NOAC with a P2Y12 inhibitor was associated with less TIMI major bleeding (OR: 0.53, 95% CrI: 0.35–0.78), TIMI major and minor bleeding (OR: 0.52, 95% CrI: 0.30–0.89), trial-defined safety outcome (OR: 0.54, 95% CrI: 0.33–0.86) and intracranial hemorrhage (OR: 0.31, 95% CrI: 0.12–0.73) compared to using VKA with DAPT (Figure 3). Here, P2RY12 is linked to intracranial hemorrhage.